scholarly journals S0896 Descriptive Assessment of Quality of Care Indicators Among Patients With Crohn’s Disease and Ulcerative Colitis in the United States

2020 ◽  
Vol 115 (1) ◽  
pp. S461-S461
Author(s):  
Casey Chapman ◽  
Jenny Griffith ◽  
Cindy Theigs ◽  
Ryan Clark ◽  
Naijun Chen
Keyword(s):  
United States ◽  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Quality Of Care ◽  
Crohn's Disease ◽  
The United States ◽  
Descriptive Assessment

TREATMENT PATTERNS OF NEWLY DIAGNOSED PEDIATRIC ULCERATIVE COLITIS AND CROHN’S DISEASE PATIENTS IN THE IMPROVECARENOW REGISTRY

2021 ◽  
Vol 27 (Supplement_1) ◽  
pp. S22-S23
Author(s):  
Theresa Hunter ◽  
Wendy Komocsar ◽  
Richard Colletti ◽  
Chunyan Liu ◽  
Keith Benkov ◽  
...  
Keyword(s):  
United States ◽  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
The United States ◽  
Current Treatment ◽  
Treatment Patterns ◽  
Initial Visit ◽  
Newly Diagnosed ◽  
Time Points

Abstract Objectives The objective of this study was to assess current treatment patterns of pediatric ulcerative colitis (UC) and Crohn’s disease (CD) patients, using data in the ImproveCareNow (ICN) registry. Methods Pediatric (2–17 years) patients in the United States who were newly diagnosed with UC or CD between June 1, 2013-December 31, 2019, who had their first recorded ICN visit within 6 months of diagnosis and who were actively followed for at least 12 months (± 90 days) were included in this study. Descriptive statistics of baseline patient demographics were summarized for the overall IBD patient population and separately for UC and CD. Treatment patterns (including use of corticosteroids, 5-aminosalicylic acid (5-ASA), 6-mercaptopurine/azathioprine (6-MP/AZA), methotrexate, tumor necrosis factor inhibitors (TNFi) [adalimumab, infliximab, certolizumab, golimumab, and their biosimilars], ustekinumab, vedolizumab, and other medications [natalizumab and tofacitinib]) were assessed at the initial baseline visit, and at 1-year and 3-year time points. Results A total of 6,504 pediatric IBD patients (UC=1,784; CD=4,720) were included in this study. Patients had a mean age at diagnosis of 13.0 years (UC=13.2; CD=12.9), 57.1% were male (UC=49.6%; CD=60.0%), and 81.0% were White (UC=81.2%; CD=81.0%) (Table 1). At the initial ICN visit, 46.4% of UC patients were prescribed a corticosteroid, while 19.8% received a 5-ASA, 12.6% received a TNFi, 10.4% received a 6-MP/AZA, 3.0% received methotrexate, and 0.3% received vedolizumab. At the initial visit, 40.2% of CD patients were prescribed a corticosteroid, while 29.1% received a TNFi, 18.5% received a 6-MP/AZA, 12.4% received methotrexate, and 3.3% received a 5-ASA. At the 1-year and 3-year time points, rates of 5-ASA and corticosteroid use decreased among UC patients; however, rates of 6-MP/AZA, methotrexate, and TNFi increased (Table 2). Similarly, at the 1-year and 3-year time points, rates of corticosteroids among CD patients decreased; however, rates of methotrexate and TNFi increased (Table 2). There was also an increase in use of ustekinumab and vedolizumab over time among UC and CD patients. Conclusion These results highlight the current treatment patterns of pediatric UC and CD patients in the United States. At the initial ICN visit, the 46% of UC and 40% of CD patients were receiving corticosteroids, however, at 1-year and 3-years after initial visit, over 30% of UC patients and over 60% of CD patients were receiving TNF inhibitors with considerably reduced corticosteroid use.

scholarly journals Incidence Rates of Ulcerative Colitis and Crohn's Disease in Fifteen Areas of the United States

1981 ◽  
Vol 81 (6) ◽  
pp. 1115-1124 ◽  
Author(s):  
Cedric F. Garland ◽  
Abraham M. Lilienfeld ◽  
Albert I. Mendeloff ◽  
Jan A. Markowitz ◽  
Katherine B. Terrell ◽  
...  
Keyword(s):  
United States ◽  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
The United States ◽  
Incidence Rates

Inflammatory Bowel Disease in the United States from 1998 to 2005: Has Infliximab Affected Surgical Rates?

2009 ◽  
Vol 75 (10) ◽  
pp. 976-980 ◽  
Author(s):  
Rebecca R. Cannom ◽  
Andreas M. Kaiser ◽  
Glenn T. Ault ◽  
Robert W. Beart ◽  
David A. Etzioni
Keyword(s):  
United States ◽  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Bowel Disease ◽  
Surgical Care ◽  
The United States ◽  
Population Based ◽  
Inflammatory Bowel

The treatment costs for patients in the United States with inflammatory bowel disease (IBD) exceed 1.7 billion dollars/year. Infliximab, an antibody to tumor necrosis factor-α, has been extensively used to treat IBD, with 390,000 IBD patients receiving the drug since its FDA approval in 1998. We sought to determine the impact of infliximab on population-based rates of hospitalizations and surgical care for patients with IBD in the United States. We used data from the Nationwide Inpatient Sample to analyze patterns of hospital-based treatment provided to patients with IBD between 1998 and 2005. Data from this analysis were combined with census data to calculate trends in population-based rates of treatment. Overall rates of hospitalization for patients with Crohn's disease and ulcerative colitis increased significantly between 1998 and 2005 (5.1%/year and 3.4%/year respectively, P < 0.001 for each). During the same time period there were no changes in the overall rates of surgical care. The expanding use of infliximab has not significantly impacted the use of surgical procedures for patients with either ulcerative colitis or Crohn's disease, and rates of nonsurgical hospitalizations have actually increased. Even in the era of infliximab, surgical care remains a mainstay in the treatment of IBD.

scholarly journals Prevalence and screening for anaemia in mild to moderate Crohn's disease and ulcerative colitis in the United States, 2010–2014

2017 ◽  
Vol 4 (1) ◽  
pp. e000155 ◽  
Author(s):  
Eboselume Akhuemonkhan ◽  
Alyssa Parian ◽  
Kay Miller ◽  
Stephen Hanauer ◽  
Susan Hutfless
Keyword(s):  
United States ◽  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
The United States

The Total Direct Cost of Healthcare in the United States in Patients with Crohn's Disease and Ulcerative Colitis: An Age Specific Analysis

2017 ◽  
Vol 152 (5) ◽  
pp. S448 ◽  
Author(s):  
Gary R. Lichtenstein ◽  
Ahva Shahabi ◽  
Seth A. Seabury ◽  
Darius Lakdawalla ◽  
Sarah G. Green ◽  
...  
Keyword(s):  
United States ◽  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Direct Cost ◽  
The United States ◽  
Total Direct Cost ◽  
Specific Analysis
Sign in / Sign up

Export Citation Format

Share Document